ReviewEuropean respiratory review : an official journal of the European Respiratory Society2012
Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis.
Review in European respiratory review : an official journal of the European Respiratory Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Current insight into the molecular mechanisms of lymphangioleiomyomatosis.American journal of respiratory cell and molecular biology · 2026Review
- Targeting fibroblast-endothelial cell interactions in LAM pathogenesis using 3D spheroid models and spatial transcriptomics.JCI insight · 2025Article
- Targeting Fibroblast-Endothelial Interactions in LAM Pathogenesis: 3D Spheroid and Spatial Transcriptomic Insights for Therapeutic Innovation.bioRxiv : the preprint server for biology · 2024Article
- Lymphangioleiomyomatosis and mTOR inhibitors in real world-a narrative review.Journal of thoracic disease · 2023Review
- The lymphatic vasculature in lung function and respiratory disease.Frontiers in medicine · 2023Review
- Eplerenone ameliorates lung fibrosis in unilateral ureteral obstruction rats by inhibiting lymphangiogenesis.Experimental and therapeutic medicine · 2022Article
- Chylous Ascites as a Presentation of Lymphangioleiomyomatosis.ACG case reports journal · 2021Article
- "T"eeing Up A Novel Therapy for Lymphangioleiomyomatosis.American journal of respiratory cell and molecular biology · 2020Article
- The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.American journal of respiratory cell and molecular biology · 2018Review
- Lymphatic Changes in Respiratory Diseases: More than Just Remodeling of the Lung?American journal of respiratory cell and molecular biology · 2017Review
- Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challenges.Advanced drug delivery reviews · 2017Review
- Lymphangiogenesis in rat asthma model.Angiogenesis · 2017Article
- Lymphangiogenesis and Lesion Heterogeneity in Interstitial Lung Diseases.Clinical medicine insights. Circulatory, respiratory and pulmonary medicine · 2015Review
- Isolation and Characterization of Human Lung Lymphatic Endothelial Cells.BioMed research international · 2015Article
- Radiation-induced impairment in lung lymphatic vasculature.Lymphatic research and biology · 2014Article
- Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer.European respiratory review : an official journal of the European Respiratory Society · 2014Review
- The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis.Frontiers in cell and developmental biology · 2014Review
- Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models.European respiratory review : an official journal of the European Respiratory Society · 2013Review
- Lymphatic endothelial differentiation in pulmonary lymphangioleiomyomatosis cells.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2013Article
- Lymphangioleiomyomatosis: current and future.Journal of thoracic disease · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The primary function of the lymphatic system is absorbing and transporting macromolecules and immune cells to the general circulation, thereby regulating fluid, nutrient absorption and immune cell trafficking. Lymphangiogenesis plays an important role in tissue inflammation and tumour cell dissemination. Lymphatic involvement is seen in lymphangioleiomyomatosis (LAM) and idiopathic pulmonary fibrosis (IPF). LAM, a disease primarily affecting females, involves the lung (cystic destruction), kidney (angiomyolipoma) and axial lymphatics (adenopathy and lymphangioleiomyoma). LAM occurs sporadically or in association with tuberous sclerosis complex (TSC). Cystic lung destruction results from proliferation of LAM cells, which are abnormal smooth muscle-like cells with mutations in the TSC1 or TSC2 gene. Lymphatic abnormalities arise from infiltration of LAM cells into the lymphatic wall, leading to damage or obstruction of lymphatic vessels. Benign appearing LAM cells possess metastatic properties and are found in the blood and other body fluids. IPF is a progressive lung disease resulting from fibroblast proliferation and collagen deposition. Lymphangiogenesis is associated with pulmonary destruction and disease severity. A macrophage subset isolated from IPF bronchoalveolar lavage fluid (BALF) express lymphatic endothelial cell markers in vitro, in contrast to the same macrophage subset from normal BALF. Herein, we review lymphatic involvement in LAM and IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.